IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|IPI-549||PIK3CG inhibitor 8||IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References||Unknown unknown||Advanced Solid Tumor||not applicable||IPI-549||Preclinical||Actionable||In a preclinical study, IPI-549 inhibited tumor growth in multiple xenograft models of solid tumors (Mol Cancer Ther December 2015 14; A192).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03795610||Phase II||IPI-549||Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma||Not yet recruiting|
|NCT02637531||Phase I||Pembrolizumab IPI-549||A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549||Recruiting|